Biognosys, Alamar Biosciences Forge Strategic Partnership In Proteomics
Portfolio Pulse from Benzinga Newsdesk
Biognosys and Alamar Biosciences have entered into a strategic partnership to expand Biognosys' services with Alamar's NULISA assays and collaborate on scientific research in biofluid-based proteomics. The partnership leverages the complementary strengths of Biognosys' DIA-MS unbiased proteomics platform and Alamar's immunoassay platforms, with findings to be presented at the AACR 2024 Annual Meeting.
April 04, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bruker Corporation (BRKR), indirectly mentioned through its association with Biognosys, may see a positive impact from the strategic partnership between Biognosys and Alamar Biosciences in expanding proteomics services and collaborative research.
Although BRKR is not directly mentioned, its association with Biognosys suggests that the partnership could enhance its position in the proteomics market. The collaboration's focus on expanding services and joint research in biofluid-based proteomics, along with the presentation of their findings at a significant annual meeting, indicates a positive development for BRKR's business in this sector.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70